Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women

Fertility and Sterility

Volumn 92, Issue 3, 2009, Pages 1039-1044

  Archer, David F ^a   Lewis, Vivian ^b   Carr, Bruce R ^c   Olivier, Sophie ^d   Pickar, James H ^d  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d PFIZER INC   (United States)

Author keywords

amenorrhea; Bazedoxifene; BZA CE; conjugated estrogens; postmenopausal; tissue selective estrogen complex; TSEC; uterine bleeding

Indexed keywords

BAZEDOXIFENE; CALCIUM; CONJUGATED ESTROGEN; PLACEBO; RALOXIFENE; VITAMIN D;

ADULT; AGED; AMENORRHEA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESTROGEN THERAPY; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; METRORRHAGIA; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPOTTING; UTERUS BLEEDING; VAGINA BLEEDING;

ADULT; AGED; AMENORRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ENDOMETRIUM; ESTROGENS; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; INCIDENCE; INDOLES; MIDDLE AGED; OUTPATIENTS; POSTMENOPAUSE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TREATMENT OUTCOME; UTERINE HEMORRHAGE;

EID: 69049112720     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2009.05.093     Document Type: Article

References (33)

1. Pinkerton J.V., and Zion A.S. Vasomotor symptoms in menopause: where we've been and where we're going. J Womens Health (Larchmt) 15 (2006) 135-145
2. Gambacciani M., and Vacca F. Postmenopausal osteoporosis and hormone replacement therapy. Minerva Med 95 (2004) 507-520
3. Maclennan A.H., Broadbent J.L., Lester S., and Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev (2004) CD002978
4. Wells G., Tugwell P., Shea B., Guyatt G., Peterson J., Zytaruk N., et al. Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev 23 (2002) 529-539
5. Hammond C.B., Jelovsek F.R., Lee K.L., Creasman W.T., and Parker R.T. Effects of long-term estrogen replacement therapy. II. Neoplasia. Am J Obstet Gynecol 133 (1979) 537-547
6. Smith D.C., Prentice R., Thompson D.J., and Herrmann W.L. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 293 (1975) 1164-1167
7. Pickar J.H., Yeh I.T., Wheeler J.E., Cunnane M.F., and Speroff L. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate: two-year substudy results. Fertil Steril 80 (2003) 1234-1240
8. Manonai J., Theppisai U., Suchartwatnachai C., Jetsawangsri T., and Chittacharoen A. Compliance with hormone replacement therapy in Thai women. Maturitas 44 (2003) 201-205
9. Wattanakumtornkul S., Chichareon S., Geater A., and Suwan K. Compliance with hormone replacement therapy at Songklanagarind Hospital. J Obstet Gynaecol Res 29 (2003) 380-387
10. Kharode Y., Bodine P.V., Miller C.P., Lyttle C.R., and Komm B.S. The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention. Endocrinology 149 (2008) 6084-6091
11. Komm B.S., and Lyttle C.R. Developing a SERM: stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation. Ann N Y Acad Sci 949 (2001) 317-326
12. Komm B.S., Kharode Y.P., Bodine P.V., Harris H.A., Miller C.P., and Lyttle C.R. Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology 146 (2005) 3999-4008
13. Ronkin S., Northington R., Baracat E., Nunes M.G., Archer D.F., Constantine G., et al. Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women. Obstet Gynecol 105 (2005) 1397-1404
14. Komm B.S. A new approach to menopausal therapy: the tissue selective estrogen complex. Reprod Sci 15 (2008) 984-992
15. Lewiecki E.M. Bazedoxifene and bazedoxifene combined with conjugated estrogens for the management of postmenopausal osteoporosis. Expert Opin Investig Drugs 16 (2007) 1663-1672
16. Berrodin T.J., Chang K.C., Komm B.S., Freedman L.P., and Nagpal S. Differential biochemical and cellular actions of premarin estrogens: distinct pharmacology of bazedoxifene-conjugated estrogens combination. Mol Endocrinol 23 (2009) 75-85
17. Peano B.J., Crabtree J.S., Komm B.S., Winneker R.C., and Harris H.A. Effects of various selective estrogen receptor modulators with or without conjugated estrogens on mouse mammary gland. Endocrinology 150 (2009) 1897-1903
18. Crabtree J.S., Peano B.J., Zhang X., Komm B.S., Winneker R.C., and Harris H.A. Activity of three selective estrogen receptor modulators on hormone-dependent responses in the mouse uterus and mammary gland. Mol Cell Endocrinol 287 (2008) 40-46
19. Carranza-Lira S., Gooch A.L., Saldivar N., and Osterwalder M.S. Climacteric symptom control after the addition of low-dose esterified conjugated estrogens to raloxifene standard doses. Int J Fertil Womens Med 52 (2007) 93-96
20. Stovall D.W., Utian W.H., Gass M.L., Qu Y., Muram D., Wong M., et al. The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety. Menopause 14 (2007) 510-517
21. Valiati B., Capp E., Edelweiss M.I., de Freitas F.M., and Wender M.C. Effect of raloxifene and low-dose percutaneous 17beta-estradiol on menopause symptoms and endometrium-a randomized controlled trial. Maturitas 62 (2009) 81-84
22. Lobo R.A., Pinkerton J.V., Gass M.L.S., Dorin M.H., Ronkin S., Pickar J.H., et al. Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil Steril 92 (2009) 1025-1038
23. Pickar J.H., Yeh I.-T., Bachmann G., and Speroff L. Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy. Fertil Steril 92 (2009) 1018-1024
24. Lindsay R., Gallagher J.C., Kagan R., Pickar J.H., and Constantine G. Efficacy of tissue-selective estrogen complex (TSEC) of bazedoxifene/conjugated estrogens (BZA/CE) for osteoporosis prevention in at-risk postmenopausal women. Fertil Steril 92 (2009) 1045-1052
25. Archer D.F., Dorin M., Lewis V., Schneider D.L., and Pickar J.H. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding. Fertil Steril 75 (2001) 1080-1087
26. Hammar M.L., van de Weijer P., Franke H.R., Pornel B., von Mauw E.M., and Nijland E.A. Tibolone and low-dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability. BJOG 114 (2007) 1522-1529
27. Papaioannou A., Kennedy C.C., Dolovich L., Lau E., and Adachi J.D. Patient adherence to osteoporosis medications: problems, consequences and management strategies. Drugs Aging 24 (2007) 37-55
28. Guay M.P., Dragomir A., Pilon D., Moride Y., and Perreault S. Changes in pattern of use, clinical characteristics and persistence rate of hormone replacement therapy among postmenopausal women after the WHI publication. Pharmacoepidemiol Drug Saf 16 (2007) 17-27
29. Archer D.F., Pickar J.H., and Bottiglioni F. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Menopause Study Group. Obstet Gynecol 83 (1994) 686-692
30. Vashisht A., Wadsworth F., Carey A., Carey B., and Studd J. Bleeding profiles and effects on the endometrium for women using a novel combination of transdermal oestradiol and natural progesterone cream as part of a continuous combined hormone replacement regime. BJOG 112 (2005) 1402-1406
31. Brzozowski A.M., Pike A.C., Dauter Z., Hubbard R.E., Bonn T., Engstrom O., et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389 (1997) 753-758
32. Katzenellenbogen B.S., Choi I., Delage-Mourroux R., Ediger T.R., Martini P.G.V., Montano M., et al. Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology. J Steroid Biochem Mol Biol 74 (2000) 279-285
33. Katzenellenbogen B.S., and Katzenellenbogen J.A. Estrogen receptor transcription and transactivation: estrogen receptor alpha and estrogen receptor beta: regulation by selective estrogen receptor modulators and importance in breast cancer. Breast Cancer Res 2 (2000) 335-344